重磅利好！市级八部门联合赋能，助推昌平医药产业跃升

Core Viewpoint - The newly issued "Measures to Support the High-Quality Development of the Pharmaceutical and Health Industry in Changping District (2026-2028)" aims to inject comprehensive policy benefits into the pharmaceutical and health industry in Changping, promoting innovative efficiency, quality development, and elevated openness for leapfrog growth [1][4]. Group 1: Policy Framework - The measures are jointly issued by eight departments including the Beijing Municipal Science and Technology Commission and the Changping District Government, focusing on cultivating a high-quality industrial ecosystem and optimizing the innovation environment [1]. - The policy emphasizes the integration of AI and healthcare innovation, enhancing technical application foundations through dual efforts in computing power support and scenario integration [3]. Group 2: Industry Development Support - The policy outlines six dimensions and seventeen specific measures to establish a comprehensive support system, focusing on key carriers such as the Zhongguancun Life Science Park and the International Medical Device City [6]. - It includes financial incentives such as a maximum of 50 million yuan for demonstration projects in AI applications within pharmaceutical research and treatment scenarios [8]. Group 3: Current Industry Landscape - Changping's pharmaceutical and health industry has a solid development foundation, with industry revenue surpassing 100 billion yuan, and significant advancements in areas like cell and gene therapy, AI in healthcare, and synthetic biology [4]. - The district is home to over 135 enterprises in the synthetic biology sector and has achieved notable milestones, including the completion of clinical implant surgeries in brain-computer interface projects [4]. Group 4: Talent and Infrastructure Development - The measures aim to create a high-level talent hub by establishing integrated living and working communities for young innovators, addressing their housing and development concerns [8]. - The policy also promotes the establishment of innovation service stations and collaborative bases to enhance the integration of education and industry, facilitating the entire pharmaceutical development and manufacturing chain [3][8].